Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.88 USD | +1.59% | +3.92% | +25.64% |
04-19 | Lake Street Starts Cellebrite DI With Buy Rating, $13 Price Target | MT |
04-01 | BofA Securities Adjusts Cellebrite DI Price Target to $13 From $12, Maintains Buy Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 68.32 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+25.64% | 2.23B | - | ||
+8.05% | 3,020B | C+ | ||
+5.58% | 82.93B | B | ||
+3.69% | 76.85B | B+ | ||
-14.62% | 53.04B | B+ | ||
+31.16% | 50.15B | D+ | ||
-24.56% | 46.71B | B- | ||
+17.75% | 41.41B | D+ | ||
+55.21% | 36.1B | D+ | ||
-10.24% | 24.64B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CLBT Stock
- Ratings Cellebrite DI Ltd.